caa a22 4500 477058310 CHVBK 20180405111353.0 cr unu---uuuuu 170330e19960201xx s 000 0 eng 10.1007/BF00203786 doi (NATIONALLICENCE)springer-10.1007/BF00203786 Penetration of pefloxacin and its desmethyl metabolite into the uroepithelium after a 800-MG single oral dose in human patients [Elektronische Daten] [J. Moreau, M. Royer-Morrot, R. Royer, A. Lozniewski, G. Trackoen, P. Delavault] Penetration of pefloxacin into the uroepithelium was studied in 20 patients (10 men and 10 women) receiving a single oral dose of 800 mg. Samples of serum, urine, and uroepithelium were taken 1.8 h (mean) after the dose. Pefloxacin and its active metabolite, norfloxacin, were assayed by liquid chromatography, and the microbiologically active compounds were quantified by a microbiological assay. Both procedures were correlated (r>0.7); nevertheless, slight differences detected in concentrations depended on the levels of norfloxacin achieved in the biological samples. The serum and tissue concentrations were higher than the concentration of bactericide (4 μg·ml−1), except in one case. The uroepithelium concentration of pefloxacin was proportional to the serum concentration (r=0.79). The urinary concentrations ranged from 1.2 μg·ml−1 to 82.4 μg·ml−1. The mean norfloxacin/pefloxacin ratios were 3% in serum, 8% in uroepithelium, and 44% in urine. The mean uroepithelium/serum concentration ratios were 1 for pefloxacin and 2.3 for norfloxacin. This result shows that, at a time close to that of the maximum concentration, there is good penetration of pefloxacin and norfloxacin into the uroepithelium. Springer-Verlag, 1996 Pefloxacin nationallicence Norfloxacin nationallicence uroepithelium nationallicence analytical methods nationallicence human patients nationallicence Moreau J. Clinique Ambroise Paré, 54000, Nancy, France aut Royer-Morrot M. Service de Pharmacologie Clinique et Toxicologie, CHU, CO 34, F-54035, Nancy Cedex, France aut Royer R. Service de Pharmacologie Clinique et Toxicologie, CHU, CO 34, F-54035, Nancy Cedex, France aut Lozniewski A. Laboratorie de Bactériologie, CO 34, F-54035, Nancy Cedex, France aut Trackoen G. Service d'Urologie, CHU, F-54511, Vandoeuvre les Nancy, France aut Delavault P. Bellon Rhône-Poulenc Rorer, BP 105, F-92201, Neuilly sur Seine Cedex, France aut European Journal of Clinical Pharmacology Springer-Verlag 49/5(1996-02-01), 401-405 0031-6970 49:5<401 1996 49 228 https://doi.org/10.1007/BF00203786 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00203786 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Moreau J. Clinique Ambroise Paré, 54000, Nancy, France aut NATIONALLICENCE 700 1- Royer-Morrot M. Service de Pharmacologie Clinique et Toxicologie, CHU, CO 34, F-54035, Nancy Cedex, France aut NATIONALLICENCE 700 1- Royer R. Service de Pharmacologie Clinique et Toxicologie, CHU, CO 34, F-54035, Nancy Cedex, France aut NATIONALLICENCE 700 1- Lozniewski A. Laboratorie de Bactériologie, CO 34, F-54035, Nancy Cedex, France aut NATIONALLICENCE 700 1- Trackoen G. Service d'Urologie, CHU, F-54511, Vandoeuvre les Nancy, France aut NATIONALLICENCE 700 1- Delavault P. Bellon Rhône-Poulenc Rorer, BP 105, F-92201, Neuilly sur Seine Cedex, France aut NATIONALLICENCE 773 0- European Journal of Clinical Pharmacology Springer-Verlag 49/5(1996-02-01), 401-405 0031-6970 49:5<401 1996 49 228 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer